CTNM vs. KURA, SDGR, ARDX, LGND, DVAX, MORF, GMTX, AVDL, SUPN, and XNCR
Should you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Kura Oncology (KURA), Schrödinger (SDGR), Ardelyx (ARDX), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), Morphic (MORF), Gemini Therapeutics (GMTX), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Kura Oncology (NASDAQ:KURA) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.
Kura Oncology's return on equity of 0.00% beat Contineum Therapeutics' return on equity.
Kura Oncology received 400 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 69.01% of users gave Kura Oncology an outperform vote.
In the previous week, Kura Oncology had 2 more articles in the media than Contineum Therapeutics. MarketBeat recorded 3 mentions for Kura Oncology and 1 mentions for Contineum Therapeutics. Kura Oncology's average media sentiment score of 1.88 beat Contineum Therapeutics' score of 0.69 indicating that Contineum Therapeutics is being referred to more favorably in the news media.
Kura Oncology presently has a consensus price target of $27.94, indicating a potential upside of 35.55%. Contineum Therapeutics has a consensus price target of $28.00, indicating a potential upside of 82.77%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Contineum Therapeutics is more favorable than Kura Oncology.
Summary
Contineum Therapeutics beats Kura Oncology on 6 of the 9 factors compared between the two stocks.
Get Contineum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Contineum Therapeutics Competitors List
Related Companies and Tools
